Mal-VC-PAB-DMEA-PNU-159682
Mal-VC-PAB-DMEA-PNU-159682 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-topoisomerase II agent, PNU-159682, linked via the lysosomally cleavable dipeptide, Mc-VC-PAB. Mal-VC-PAB-DMEA-PNU-159682 can be used in the synthesis of Anti-CD22-NMS249 (HY-164761) [1].
Product Specifications
CAS Number
[1178887-17-6]
Product Name Alternative
SET0568
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
OC1=C2C(C(C3=C(OC)C=CC=C3C2=O)=O)=C(O)C([C@H]4O[C@H]5C[C@]6([H])N7[C@]([C@H](OCC7)OC)([H])O[C@]6([H])[C@@H](O5)C)=C1C[C@](O)(C4)C(COC(N(C)CCN(C)C(OCC8=CC=C(C=C8)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN9C(C=CC9=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C66H83N9O22
Molecular Weight
1354.41
References & Citations
[1]Shang-Fan Yu, et al. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clin Cancer Res. 2015 Jul 15;21 (14) :3298-306.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
